Companies Dominating the Malaria Ag Rapid Testing Landscape
- Wyss Institute
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Alere, Inc.
- Nectar Lifesciences Ltd.
- Teco Diagnostics
- Xiamen Boson Biotech Co. Ltd.
- HWTAi BioTec
- Arkray Inc.
- CTK Biotech Inc.
- Biosynex SA
Browse Key Market Insights with Data Illustration:
In the News
- A multidisciplinary research team led by James Collins, Ph.D., a member of the Wyss Core Faculty at the Massachusetts Institute of Technology (MIT) and Harvard's Wyss Institute for Biologically Inspired Engineering, and put together by clinical fellow Rose Lee, M.D., M.S.P.H., along with Pollock and Dvorin, has developed a highly sensitive diagnostic assay that can be used in the field to identify DNA sequences from all Plasmodium species in both symptomatic and asymptomatic cases of malaria. With the help of the CRISPR-based SHERLOCK system and an optimised 10-minute quick sample preparation technique, the novel malaria diagnostic approach allows for extremely sensitive and specific Plasmodium identification in just 60 minutes using straightforward reporter devices. The publication is in PNAS.
- In response to the growing concern of resistance to existing malaria treatments1,2, Novartis and MMV have decided to move ganaplacide/lumefantrine solid dispersion formulation (SDF) into Phase 3 development for the treatment of individuals suffering from acute, uncomplicated Plasmodium falciparum malaria.
